Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Triple Negative Breast Neoplasms × taxane × Clear all

Status

Sponsor Class

Study Type

Interventional 5 Observational 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 2 Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Blood Specimen Collection 4 Drug Therapy 3 Specimen Handling 2 Immune Checkpoint Inhibitors 2 Carboplatin 2 Biopsy, Large-Core Needle 2 Biopsy 2 toripalimab 1 tislelizumab 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 Zoledronic Acid 1 Prophylactic Mastectomy 1 Paracentesis 1 Neuropsychological Tests 1 Mifepristone 1 Medicine, Chinese Traditional 1 Mastectomy, Segmental 1 Magnetic Resonance Spectroscopy 1 Magnetic Resonance Imaging 1 Interviews as Topic 1 Immunotherapy 1 Immunohistochemistry 1 Gene Expression Profiling 1 Doxorubicin 1 DNA 1 Cyclophosphamide 1 Combined Modality Therapy 1 Colonoscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05916755 2023-06-23

PORTRAIT

Vall d'Hebron Institute of Oncology

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡